{"pmid":32407707,"pmcid":"PMC7219357","title":"Rational Vaccine Design in the Time of COVID-19.","text":["Rational Vaccine Design in the Time of COVID-19.","As scientists consider SARS-CoV-2 vaccine design, we discuss problems that may be encountered and how to tackle them by what we term \"rational vaccine design.\" We further discuss approaches to pan-coronavirus vaccines. We draw on experiences from recent research on several viruses including HIV and influenza, as well as coronaviruses.","Cell Host Microbe","Burton, Dennis R","Walker, Laura M","32407707"],"abstract":["As scientists consider SARS-CoV-2 vaccine design, we discuss problems that may be encountered and how to tackle them by what we term \"rational vaccine design.\" We further discuss approaches to pan-coronavirus vaccines. We draw on experiences from recent research on several viruses including HIV and influenza, as well as coronaviruses."],"journal":"Cell Host Microbe","authors":["Burton, Dennis R","Walker, Laura M"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407707","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.04.022","topics":["Treatment"],"weight":1,"_version_":1666950579768786945,"score":9.490897,"similar":[{"pmid":32295153,"title":"What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?","text":["What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?","The emergence of new pathogenic viral strains is a constant threat to global health, with the new coronavirus strain COVID-19 as the latest example. COVID-19, caused by the SARS-CoV-2 virus has quickly spread around the globe. This pandemic demands rapid development of drugs and vaccines. Plant-based vaccines are a technology with proven viability, which have led to promising results for candidates evaluated at the clinical level, meaning this technology could contribute towards the fight against COVID-19. Herein, a perspective in how plant-based vaccines can be developed against COVID-19 is presented. Injectable vaccines could be generated by using transient expression systems, which offer the highest protein yields and are already adopted at the industrial level to produce VLPs-vaccines and other biopharmaceuticals under GMPC-processes. Stably-transformed plants are another option, but this approach requires more time for the development of antigen-producing lines. Nonetheless, this approach offers the possibility of developing oral vaccines in which the plant cell could act as the antigen delivery agent. Therefore, this is the most attractive approach in terms of cost, easy delivery, and mucosal immunity induction. The development of multiepitope, rationally-designed vaccines is also discussed regarding the experience gained in expression of chimeric immunogenic proteins in plant systems.","Vaccines (Basel)","Rosales-Mendoza, Sergio","Marquez-Escobar, Veronica A","Gonzalez-Ortega, Omar","Nieto-Gomez, Ricardo","Arevalo-Villalobos, Jaime I","32295153"],"abstract":["The emergence of new pathogenic viral strains is a constant threat to global health, with the new coronavirus strain COVID-19 as the latest example. COVID-19, caused by the SARS-CoV-2 virus has quickly spread around the globe. This pandemic demands rapid development of drugs and vaccines. Plant-based vaccines are a technology with proven viability, which have led to promising results for candidates evaluated at the clinical level, meaning this technology could contribute towards the fight against COVID-19. Herein, a perspective in how plant-based vaccines can be developed against COVID-19 is presented. Injectable vaccines could be generated by using transient expression systems, which offer the highest protein yields and are already adopted at the industrial level to produce VLPs-vaccines and other biopharmaceuticals under GMPC-processes. Stably-transformed plants are another option, but this approach requires more time for the development of antigen-producing lines. Nonetheless, this approach offers the possibility of developing oral vaccines in which the plant cell could act as the antigen delivery agent. Therefore, this is the most attractive approach in terms of cost, easy delivery, and mucosal immunity induction. The development of multiepitope, rationally-designed vaccines is also discussed regarding the experience gained in expression of chimeric immunogenic proteins in plant systems."],"journal":"Vaccines (Basel)","authors":["Rosales-Mendoza, Sergio","Marquez-Escobar, Veronica A","Gonzalez-Ortega, Omar","Nieto-Gomez, Ricardo","Arevalo-Villalobos, Jaime I"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295153","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.3390/vaccines8020183","keywords":["epitope-based vaccine","molecular farming","mucosal immunization","multiepitope vaccine","oral vaccines","zoonosis"],"topics":["Treatment"],"weight":1,"_version_":1666138493268525057,"score":88.945656},{"pmid":32318915,"pmcid":"PMC7174145","title":"Vaccine confidence in the time of COVID-19.","text":["Vaccine confidence in the time of COVID-19.","In the early months of the COVID-19 epidemic, some have wondered if the force of this global experience will solve the problem of vaccine refusal that has vexed and preoccupied the global public health community for the last several decades. Drawing on historical and epidemiological analyses, we critique contemporary approaches to reducing vaccine hesitancy and articulate our notion of vaccine confidence as an expanded way of conceptualizing the problem and how to respond to it. Intervening on the rush of vaccine optimism we see pervading present discourse around the COVID-19 epidemic, we call for a re-imagination of the culture of public health and the meaning of vaccine safety regulations. Public confidence in vaccination programs depends on the work they do for the community-social, political, and moral as well as biological. The concept of public health and its programs must be broader than the delivery of the vaccine technology itself. The narrative work and policy actions entailed in actualizing such changes will, we expect, be essential in achieving a true vaccine confidence, however the public reacts to the specific vaccine that may be developed for COVID-19.","Eur J Epidemiol","Harrison, Emily A","Wu, Julia W","32318915"],"abstract":["In the early months of the COVID-19 epidemic, some have wondered if the force of this global experience will solve the problem of vaccine refusal that has vexed and preoccupied the global public health community for the last several decades. Drawing on historical and epidemiological analyses, we critique contemporary approaches to reducing vaccine hesitancy and articulate our notion of vaccine confidence as an expanded way of conceptualizing the problem and how to respond to it. Intervening on the rush of vaccine optimism we see pervading present discourse around the COVID-19 epidemic, we call for a re-imagination of the culture of public health and the meaning of vaccine safety regulations. Public confidence in vaccination programs depends on the work they do for the community-social, political, and moral as well as biological. The concept of public health and its programs must be broader than the delivery of the vaccine technology itself. The narrative work and policy actions entailed in actualizing such changes will, we expect, be essential in achieving a true vaccine confidence, however the public reacts to the specific vaccine that may be developed for COVID-19."],"journal":"Eur J Epidemiol","authors":["Harrison, Emily A","Wu, Julia W"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32318915","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s10654-020-00634-3","keywords":["covid-19","culture","historical","vaccine confidence","vaccine hesitancy","vaccine safety regulation"],"topics":["Treatment"],"weight":1,"_version_":1666138493706829824,"score":88.550804},{"pmid":32468631,"title":"Vaccine Rationing and the Urgency of Social Justice in the Covid-19 Response.","text":["Vaccine Rationing and the Urgency of Social Justice in the Covid-19 Response.","The Covid-19 pandemic needs to be considered from two perspectives simultaneously. First, there are questions about which policies are most effective and fair in the here and now, as the pandemic unfolds. These polices concern, for example, who should receive priority in being tested, how to implement contact tracing, or how to decide who should get ventilators or vaccines when not all can. Second, it is imperative to anticipate the medium- and longer-term consequences that these policies have. The case of vaccine rationing is particularly instructive. Ethical, epidemiological, and economic reasons demand that rationing approaches give priority to groups who have been structurally and historically disadvantaged, even if this means that overall life years gained may be lower.","Hastings Cent Rep","Schmidt, Harald","32468631"],"abstract":["The Covid-19 pandemic needs to be considered from two perspectives simultaneously. First, there are questions about which policies are most effective and fair in the here and now, as the pandemic unfolds. These polices concern, for example, who should receive priority in being tested, how to implement contact tracing, or how to decide who should get ventilators or vaccines when not all can. Second, it is imperative to anticipate the medium- and longer-term consequences that these policies have. The case of vaccine rationing is particularly instructive. Ethical, epidemiological, and economic reasons demand that rationing approaches give priority to groups who have been structurally and historically disadvantaged, even if this means that overall life years gained may be lower."],"journal":"Hastings Cent Rep","authors":["Schmidt, Harald"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468631","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/hast.1113","keywords":["covid-19","health disparities","public health ethics","public health policies","social justice","vaccine rationing"],"weight":0,"_version_":1668167109942706176,"score":87.92725},{"pmid":32419646,"title":"Design of multi-epitope vaccine candidate against SARS-CoV-2: a In-Silico study.","text":["Design of multi-epitope vaccine candidate against SARS-CoV-2: a In-Silico study.","The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silica tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.","J Biomol Struct Dyn","K, Abraham Peele","T, Srihansa","S, Krupanidhi","A, Vijaya Sai","Tc, Venkateswarulu","32419646"],"abstract":["The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silica tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19."],"journal":"J Biomol Struct Dyn","authors":["K, Abraham Peele","T, Srihansa","S, Krupanidhi","A, Vijaya Sai","Tc, Venkateswarulu"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419646","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/07391102.2020.1770127","keywords":["covid-19","iedb","spike glycoprotein","vaccine design","vaxigen","immuno-informatics"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284572487682,"score":82.90703},{"pmid":32348165,"title":"Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.","text":["Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.","The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.","Health Secur","Billington, John","Deschamps, Isabelle","Erck, Stanley C","Gerberding, Julie L","Hanon, Emmanuel","Ivol, Sabrina","Shiver, John W","Spencer, Julia A","Van Hoof, Johan","32348165"],"abstract":["The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines."],"journal":"Health Secur","authors":["Billington, John","Deschamps, Isabelle","Erck, Stanley C","Gerberding, Julie L","Hanon, Emmanuel","Ivol, Sabrina","Shiver, John W","Spencer, Julia A","Van Hoof, Johan"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348165","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1089/hs.2020.0043","keywords":["covid-19","epidemic management/response","infectious diseases","sars-cov-2","vaccine development"],"topics":["Treatment"],"weight":1,"_version_":1666138495425445888,"score":82.216644}]}